Skip to content

Advancing breast cancer research in Japan using EHR-derived real-world data

Published

April 2025

Citation

Adamson B, Ng D, Pittell H, et al. Advancing breast cancer research in Japan using EHR-derived real-world data. Presented at ISPOR Annual. 2025.

 

Overview

Breast cancer is the most commonly diagnosed cancer among women in Japan, yet there is limited real-world evidence (RWE) available to understand treatment patterns and patient outcomes in routine clinical practice. This study introduces the Flatiron Health Japan Breast Cancer dataset, a novel, de-identified real-world database derived from structured and unstructured data collected from routine oncology care and stored within electronic health record (EHR) and relevant hospital information systems in Japan. 

The dataset demonstrated high completeness and alignment with clinical expectations for key clinical variables such as detailed cancer diagnosis information, biomarker test results, and treatment details, making it a reliable and valuable resource for evaluating treatment effectiveness and patient outcomes.

Why this matters

This dataset provides critical real-world insights into breast cancer care in Japan, and will be a critical resource to enhance researchers’ and clinicians’ understanding of treatment effectiveness and patient outcomes in the real-world setting. By enabling comparative effectiveness studies and cross-country analyses in combination with Flatiron Health’s multinational real-world datasets, future research utilizing this dataset can inform better treatment strategies and policy decisions, ultimately improving care for breast cancer patients both in Japan and globally.

Share